Literature DB >> 31344596

Study of association of the rs2275913 IL-17A single nucleotide polymorphism and susceptibility to cutaneous leishmaniasis caused by Leishmania braziliensis.

Suênia da Cunha Gonçalves de Albuquerque1, Cíntia Nascimento da Costa Oliveira2, Victor Vaitkevicius-Antão2, Ana Carla Silva2, Carlos Feitosa Luna2, Virgínia Maria Barros de Lorena3, Milena de Paiva-Cavalcanti4.   

Abstract

Cutaneous leishmaniasis (CL) caused by Leishmania braziliensis is the most spread clinical form of leishmaniasis in Brazil. However, only a few part of the people infected develop clinically perceptive disease, suggesting the influence of human genetic components in the CL pathogeny. The rs2275913 SNP is the nucleotide variant of the IL17A gene. The A allele is associated with a vast number of infectious and non-infectious diseases. Here, we investigated the association of the rs2275913 SNP (G/A) from IL-17A and two forms of susceptibility to CL in Brazil by case-control study. Furthermore, we evaluated the functional relevance of this SNP during the immune response of the host and analyzed its impact in the parasite elimination. Weak associations of A allele with susceptibility to L. braziliensis infection or to symptomatic CL were observed, and a tendency of A allele carriers to be more susceptible to infection and cutaneous disease. Functional analysis of the Th17 cell phenotypes revealed lower frequencies of CD4+ IL-17+ cells in samples of infected people with AA/AG genotypes. Furthermore, people carrying the A allele maintain higher parasite loads, reinforcing the genetic susceptibility findings. This study adds knowledge about the influence of a significant genetic variation on IL-17 promoter on CL pathogenesis, and may contribute to enhance the knowledge about the role of IL-17 in the L. braziliensis infections.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cutaneous leishmaniasis; Immunopathogenesis; Interleukin 17; SNP; Th17 cells

Year:  2019        PMID: 31344596     DOI: 10.1016/j.cyto.2019.154784

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population.

Authors:  Natalia Aranza Zapata-Salazar; David Emmanuel Kubelis-Lopez; Mauricio Andres Salinas-Santander; Celia Nohemi Sanchez-Dominguez; Ana Cecilia Xolalpa-Rosales; Marely Eugenia Gomez-Galindo; Jorge Ocampo-Candiani
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

2.  The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment.

Authors:  Mehdi Ghazanfari; Bahador Shahriari; Vahid Rahnama; Meisam Khazaei; Shahrbanou Naderi; Mohammad Hossein Motazedian
Journal:  J Parasit Dis       Date:  2022-02-03

3.  Immunoprophylactic Potential of a New Recombinant Leishmania infantum Antigen for Canine Visceral Leishmaniasis: An In Vitro Finding.

Authors:  Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Victor Vaitkevicius-Antão; Wagner José Tenório Dos Santos; Franklin Barbalho Magalhães; Danielle Maria Nascimento Moura; Eiji Kevin Nakasone Nakasone; Virgínia Maria Barros de Lorena; Milena de Paiva-Cavalcanti
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 4.  The Role of Immunogenetics in COVID-19.

Authors:  Fanny Pojero; Giuseppina Candore; Calogero Caruso; Danilo Di Bona; David A Groneberg; Mattia E Ligotti; Giulia Accardi; Anna Aiello
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

5.  Genetic polymorphisms of IL17A associated with Chagas disease: results from a meta-analysis in Latin American populations.

Authors:  Mariana Strauss; Miriam Palma-Vega; Desiré Casares-Marfil; Pau Bosch-Nicolau; María Silvina Lo Presti; Israel Molina; Clara Isabel González; Javier Martín; Marialbert Acosta-Herrera
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.